These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10416826)

  • 1. The effect of therapeutic drugs and other pharmacologic agents on activity of porphobilinogen deaminase, the enzyme that is deficient in intermittent acute porphyria.
    Tishler PV
    Life Sci; 1999; 65(2):207-14. PubMed ID: 10416826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
    Johansson A; Möller C; Fogh J; Harper P
    Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France.
    Nordmann Y; Puy H; Da Silva V; Simonin S; Robreau AM; Bonaiti C; Phung LN; Deybach JC
    J Intern Med; 1997 Sep; 242(3):213-7. PubMed ID: 9350165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Blomberg P; Harper P
    Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria. Immunologic evidence for heterogeneity of the genetic defect.
    Anderson PM; Reddy RM; Anderson KE; Desnick RJ
    J Clin Invest; 1981 Jul; 68(1):1-12. PubMed ID: 7251856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.
    San Juan I; Pereira-Ortuzar T; Cendoya X; Laín A; To-Figueras J; Mateos B; Planes FJ; Bernardo-Seisdedos G; Mato JM; Millet O
    Biochemistry; 2022 Nov; 61(21):2409-2416. PubMed ID: 36241173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.
    Desnick RJ; Ostasiewicz LT; Tishler PA; Mustajoki P
    J Clin Invest; 1985 Aug; 76(2):865-74. PubMed ID: 3897290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of acute intermittent porphyria: a subtype with normal erythrocyte porphobilinogen deaminase activity in Germany.
    Gross U; Honcamp M; Doss MO
    Eur J Clin Chem Clin Biochem; 1996 Aug; 34(8):613-8. PubMed ID: 8877336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual activity of human porphobilinogen deaminase with R167Q or R167W mutations: an explanation for survival of homozygous and compound heterozygous acute intermittent porphyrics.
    Edixhoven-Bosdijk A; de Rooij FW; de Baar-Heesakkers E; Wilson JH
    Cell Mol Biol (Noisy-le-grand); 2002 Dec; 48(8):861-6. PubMed ID: 12699244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
    Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
    PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
    Ulbrichova D; Hrdinka M; Saudek V; Martasek P
    FEBS J; 2009 Apr; 276(7):2106-15. PubMed ID: 19292878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute intermittent porphyria: mutation analysis and identification of gene carriers in a German kindred by PCR-DGGE analysis.
    Petrides PE
    Skin Pharmacol Appl Skin Physiol; 1998; 11(6):374-80. PubMed ID: 10343207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and evaluation of two porphobilinogen deaminase activity assays for diagnosis of acute intermittent porphyria.
    Lin CN; Huang YC; Ro LS; Liao MF; Ning HC; Kuo HC
    Clin Chim Acta; 2018 Apr; 479():1-6. PubMed ID: 29317194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute intermittent porphyria: laboratory diagnosis by molecular methods.
    Schreiber WE
    Clin Lab Med; 1995 Dec; 15(4):943-56. PubMed ID: 8838232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.
    Herrick AL; McColl KE; Moore MR; Brodie MJ; Adamson AR; Goldberg A
    Br J Clin Pharmacol; 1989 Apr; 27(4):491-7. PubMed ID: 2497768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in acute intermittent porphyria detected by ELISA measurement of porphobilinogen deaminase.
    Lannfelt L; Wetterberg L; Gellerfors P; Lilius L; Floderus Y; Thunell S
    J Clin Chem Clin Biochem; 1989 Nov; 27(11):857-62. PubMed ID: 2607315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.